Dec. 8, 2020 Price forecast | 2 weeks: 8.09% | 1 month: 8.08% | 3 months: 5.51%

HEPA stock forecast

Our latest prediction for Hepion Pharmaceuticals Inc's stock price was made on the Dec. 8, 2020 when the stock price was at 1.70$.

In the short term (2weeks), HEPA's stock price should outperform the market by 8.09%. During that period the price should oscillate between -11.79% and +31.63%.

In the medium term (3months), HEPA's stock price should outperform the market by 5.51%. During that period the price should oscillate between -46.23% and +79.42%.

Create a solid portfolio with HEPA

Add HEPA to your portfolio and optimize it!

About Hepion Pharmaceuticals Inc

The Company's lead drug candidate, CRV431, is a potent inhibitor of cyclophilins, which are involved in many disease processes. CRV431 is currently in clinical-phase development for the treatment of NASH, with the potential to play an important role in the overall treatment of liver disease - from triggering events through to end-stage disease. CRV431 has been shown to reduce liver fibrosis and hepatocellular carcinoma tumor burden in experimental models of NASH; and has demonstrated antiviral activities towards HBV, HCV, and HDV through several mechanisms, in preclinical studies. Hepion has created a proprietary AI platform, called AI-POWR™, which stands for Artificial Intelligence - Precision Medicine; Omics (including genomics, proteomics, metabolomics, transcriptomics, and lipidomics); World database access; and Response and clinical outcomes. Hepion intends to use AI-POWR™ to help identify which NASH patients will best respond to CRV431, potentially shortening development timelines and increasing the delta between placebo and treatment groups. In addition to using AI-POWR™ to drive its ongoing Phase 2a NASH program, Hepion will use the platform to identify additional potential indications for CRV431 to expand the company's footprint in the cyclophilin inhibition therapeutic space.

At the moment the company doesn't generate any revenue.

On its last earning announcement, the company reported a loss of -1.36$ per share.

The book value per share is 1.24$

Hepion Pharmaceuticals Inc website

Three months stock forecastDec. 8, 2020


Revenue USD Gross Margin Operating Income Operating Margin Net Income Earnings Per Share Dividends Payout Ratio Shares Book Value Per Share Operating Cash Flow Cap Spending Free Cash Flow
- - -17M - -17M -1.36 - - 6M 1.24 -14M - -14M